SRA's number for the day: 19
This article was originally published in SRA
Executive Summary
A total of 19 pharmaceutical companies between 2009 and 2012 failed to submit one or more annual reports on deferred measures relating to paediatric investigation plans (PIPs) for authorized medicines, as required by the EU Paediatric Regulation1.
You may also be interested in...
Migraine & Hepatitis B Prevention Products Among New EU Filings
The latest list of marketing authorization applications under review by the European Medicines Agency includes filings for eight new products.
Another EU Filing Targets Burgeoning NMOSD Market
Viela and Roche both now have marketing applications that are being reviewed by the European Medicines Agency. If approved in the EU, their products will compete with Alexion’s blockbuster Soliris.
Big Changes Kicking In Under Australia’s Personalized Medical Devices Rules
Most of the products currently supplied under Australia’s custom-made medical device exemption will no longer be eligible for supply in this way.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: